# Insilico Medicine

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/insilico-medicine
Canonical HTML page: https://getbiobrief.com/entity/insilico-medicine

## Timeline

- **2026-03-06**: Phase I Initiation — First human subject enrolled and dosed in the Phase I clinical trial.
- **2025-Q1**: Out-Licensing Deal — TaiGen Biopharmaceuticals acquires rights for clinical development and commercialization.
- **2024-Q2**: Candidate Discovery — Insilico Medicine identifies ISM4808 using generative AI models.

## Recent coverage (3 stories)

### Multi-Target AI Alliance Targets $2.5B Potential to Redraw Pharma R&D Model
2026-07-15 03:35:52 · Sentiment: Positive · Impact: 7/10 · Sources: 3

The proposed alliance between AI powerhouse Insilico Medicine and CDMO Bora Pharmaceuticals could create a seamless pipeline from generative chemistry to commercial manufacturing. With a headline potential of over $2.5 billion, the deal targets multiple therapeutic programs and directly addresses the translational gap that often stalls promising drug candidates.
Full story: https://getbiobrief.com/story/insilico-bora-ai-pharma-pipeline

### Insilico's $2.5B AI CNS Biobucks Deal With SK Bio Sets APAC Record
2026-06-23 04:57:27 · Sentiment: Strongly positive · Impact: 8/10 · Sources: 2

In the largest Asia‑Pacific licensing deal for Insilico Medicine, the AI‑first biotech secured up to $2.5 billion in milestones plus royalties from South Korea's SK Biopharmaceuticals, a CNS powerhouse, to co‑develop next‑generation neuroimmune therapies. The heavily back‑ended structure reflects industry‑standard risk‑sharing, with Insilico taking $18M up front and SK steering commercialization, underscoring a growing appetite for AI‑discovered assets in big pharma pipelines.
Full story: https://getbiobrief.com/story/insilico-sk-biopharma-2-5b-biobucks-record-apac

### Insilico and TaiGen Advance AI-Derived CKD Anemia Candidate to Phase I
2026-03-06 12:39:49 · Sentiment: Positive · Impact: 6/10 · Sources: 3

Insilico Medicine and TaiGen Biopharmaceuticals have achieved a major clinical milestone with the first human dosing of ISM4808, an AI-discovered small molecule for Chronic Kidney Disease (CKD) anemia. This Phase I trial marks a critical validation point for Insilico’s Pharma.AI platform and triggers a milestone payment from TaiGen.
Full story: https://getbiobrief.com/story/insilico-taigen-ism4808-phase-1-clinical-trial

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.